Cardiovascular Diabetology

1. Cardiovasc Diabetol29 Apr 2026

   Metabolomic signatures of hepatic steatosis reveal heterogeneity in cardiometabolic risk and responses to lifestyle interventions in type 2 diabetes: a post hoc analysis

   Secondary analysisT2D & other

2. Cardiovasc Diabetol28 Apr 2026

   Synergistic effects of insulin resistance and revascularization completeness on prognosis in patients with coronary artery calcification

   Cohort studyComplications

3. Cardiovasc Diabetol28 Apr 2026

   Obesity and insulin resistance trigger the early onset of adolescent-like sexually dimorphic metabotypes in middle childhood

   Cross-sectional studyObesity

4. Cardiovasc Diabetol27 Apr 2026

   Changes in the estimated glucose disposal rate and cardiometabolic multimorbidity in middle-aged and older adults

   Cohort studyT2D & other

5. Cardiovasc Diabetol27 Apr 2026

   Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in metabolic-dysfunction associated steatotic liver disease: evidence from two cohort studies

   Cohort studyLipids & liver

6. Cardiovasc Diabetol26 Apr 2026

   LDL-C combined with Chinese visceral adiposity index as a risk stratification tool for cardiometabolic multimorbidity in middle-aged and older Chinese adults: a national prospective cohort study

   Cohort studyLipids & liver

7. Cardiovasc Diabetol26 Apr 2026

   Metabolic status modifies the predictive value of the C-reactive protein–triglyceride–glucose Index–waist-to-height ratio for major adverse cardiovascular and cerebrovascular events: a prospective cohort study from the China Health and Retirement Longitudinal Study (CHARLS)

   Cohort studyT2D & other

8. Cardiovasc Diabetol24 Apr 2026

   Comprehensive evaluation of the triglyceride glucose index (TyG) and body roundness index (BRI) on cardiovascular disease risk prediction: a 9-year prospective cohort study in Chinese middle-aged and older adults

   Cohort studyLipids & liver

9. Cardiovasc Diabetol22 Apr 2026

   Novel OGTT metrics do not provide incremental predictive value beyond conventional glycemic criteria for remission of prediabetes in individuals with impaired fasting glucose: results from the PREVIEW trial

   Secondary analysisT2D & other

10. Cardiovasc Diabetol21 Apr 2026

    Association of various insulin resistance surrogate markers with mortality risk in critically ill patients with ischemic stroke: a retrospective cohort study

    Cohort studyComplications

11. Cardiovasc Diabetol20 Apr 2026

    Continuous glucose monitoring trajectories in patients with acute coronary syndrome

    Cohort studyTechnology

12. Cardiovasc Diabetol14 Apr 2026

    Diabetes does not attenuate the benefit of physiology-guided complete revascularization in older patients with myocardial infarction

    Secondary analysisT2D & other

13. Cardiovasc Diabetol13 Apr 2026

    The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict diabetic kidney disease development and progression: evidence from two nationwide cohorts and a biopsy-proven clinical cohort

    Diagnostic or prognostic studyComplications

14. Cardiovasc Diabetol12 Apr 2026

    Cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index (CTI) versus the cholesterol, high-density lipoprotein, and glucose index (CHG) for incident hypertension prediction: a national cohort study

    Cohort studyLipids & liver

15. Cardiovasc Diabetol11 Apr 2026

    Association of cumulative exposure and change patterns of triglyceride–glucose index combined with novel obesity indices with glycemic transitions in prediabetes: evidence from the China Health and Retirement Longitudinal Study (CHARLS)

    Cohort studyT2D & other

16. Cardiovasc Diabetol9 Apr 2026

    Hepatic metabolic burden and all-cause mortality across glucose metabolism statuses in a cardiovascular-kidney-metabolic syndrome population: insights from the National Health and Nutrition Examination Survey (NHANES)

    Cohort studyT2D & other

17. Cardiovasc Diabetol9 Apr 2026

    Diabetes-related differences in body composition and their prognostic value among patients with heart failure and preserved ejection fraction: a cardiac-MRI-based study

    Cohort studyT2D & other

18. Cardiovasc Diabetol6 Apr 2026

    The prognostic significance of cholesterol, high-density lipoprotein and glucose (CHG) index in evaluating all-cause mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) individuals: evidence from two cohort studies

    Cohort studyLipids & liver

19. Cardiovasc Diabetol5 Apr 2026

    Associations between the C-reactive protein-triglyceride glucose index and the incidence and progression trajectory of cardiometabolic multimorbidity: a multi-state model study

    Cohort studyT2D & other

20. Cardiovasc Diabetol5 Apr 2026

    Assessment of seven insulin resistance surrogate indexes for predicting cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study

    Cohort studyT2D & other

21. Cardiovasc Diabetol4 Apr 2026

    The association between liver fat content and plasma metabolite profiles in fasting and postprandial states: an integration of a cohort study and a randomized controlled trial

    Randomized controlled trialLipids & liver

22. Cardiovasc Diabetol3 Apr 2026

    Joint association of triglyceride-glucose (TyG) and atherogenic index of plasma (AIP) with stroke risk: findings from a nationwide prospective cohort

    Cohort studyLipids & liver

23. Cardiovasc Diabetol3 Apr 2026

    Novel amino acid and fatty acid signatures linked to type 2 diabetes risk after gestational diabetes mellitus

    Cohort studyDiabetes in pregnancy

24. Cardiovasc Diabetol3 Apr 2026

    Collective exerkines mediate physical activity mitigating new-onset heart failure risk in older adults with prediabetes or diabetes: a community-based longitudinal cohort study

    Cohort studyT2D & other

25. Cardiovasc Diabetol1 Apr 2026

    Association of the C-reactive protein–triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study

    Cohort studyLipids & liver

26. Cardiovasc Diabetol1 Apr 2026

    Association of C-reactive protein-triglycerides-glucose index-waist to height ratio and cardiometabolic multimorbidity in middle-aged and older adults: a nationwide cohort study

    Cohort studyT2D & other

27. Cardiovasc Diabetol31 Mar 2026

    Associations of the triglyceride-glucose index and its obesity-related derivatives with cardiac structure, function, and incident atrial fibrillation: a prospective cohort study using cardiac magnetic resonance

    Secondary analysisObesity

28. Cardiovasc Diabetol30 Mar 2026

    High inflammatory burden may link non-albuminuric diabetic kidney disease to carotid atherosclerosis

    Cross-sectional studyComplications

29. Cardiovasc Diabetol30 Mar 2026

    Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study

    Cohort studyT2D & other

30. Cardiovasc Diabetol30 Mar 2026

    Associations of eight insulin resistance-related indices and genetic risk with incident cardiometabolic multimorbidity among participants with hypertension: a large prospective cohort study

    Cohort studyT2D & other

31. Cardiovasc Diabetol30 Mar 2026

    Phenotypic heterogeneity of type 2 diabetes and risks of complications with a tree-like representation

    Cohort studyT2D & other

32. Cardiovasc Diabetol29 Mar 2026

    Associations of cumulative exposure and dynamic trajectories of the triglyceride–total cholesterol–body weight index with new-onset cardiometabolic multimorbidity in middle-aged and older Chinese adults: evidence from a nationwide prospective cohort study

    Cohort studyLipids & liver

33. Cardiovasc Diabetol28 Mar 2026

    Association between triglyceride-glucose index and related indicators with heart failure–related mortality in individuals with early-stage cardiovascular-kidney-metabolic syndrome

    Cohort studyLipids & liver

34. Cardiovasc Diabetol28 Mar 2026

    Association between estimated glucose disposal rate and incident heart failure in patients with coronary heart disease: a prospective cohort study

    Cohort study

35. Cardiovasc Diabetol28 Mar 2026

    Multiblock proteomic profiling identifies novel biomarkers linking prediabetes with preclinical atherosclerosis in apparently healthy adults

    Cross-sectional studyT2D & other

36. Cardiovasc Diabetol28 Mar 2026

    Modulation of PKCα/ETS1 by klotho restores CYB5R4-dependent mitochondrial function in proximal tubular epithelial cells to attenuate the progression of diabetic kidney disease

    Mechanistic studyComplications

37. Cardiovasc Diabetol26 Mar 2026

    The joint association of the combined triglyceride-glucose index and atherogenic index of plasma with hypertension on stroke risk across different glycemic status: a prospective cohort study

    Cohort study

38. Cardiovasc Diabetol26 Mar 2026

    Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

    Secondary analysisT2D & other

39. Cardiovasc Diabetol26 Mar 2026

    Associations of triglyceride–glucose-related composite obesity indices with cardiovascular diseases and mortality: a systematic review and meta-analysis

    Meta-analysisObesity

40. Cardiovasc Diabetol26 Mar 2026

    Circulating amino acids and Type 2 diabetes in a Latin American population-based cohort

    Cohort studyT2D & other

All 1,291 Briefs in ExploreShowing Briefs 121–160 of 1,291, newest first